Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Integrilin

(eptifibatide)

ApprovedPeptide

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Eptifibatide is used to prevent blood clots and reduce the risk of heart attack or stent thrombosis in patients undergoing heart procedures or experiencing acute coronary syndrome (unstable angina or heart attack).[2] Integrilin is currently approved and in use across 10 indications[4].[1]

Integrilin is one of 237 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

10

Indications

21

Total Trials

1

Active Trials

236

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Cardiovascular DiseaseApproved

Intermediate Coronary SyndromeActive, not recruiting

Acute Coronary SyndromeCompleted

Acute Myocardial InfarctionApproved

NecrosisTerminated

Myocardial InfarctionActive, not recruiting

Recurrent ThrombophlebitisActive, not recruiting

Myocardial IschemiaApproved

Brain InfarctionApproved

Septic ShockApproved

Cardiovascular DiseaseApproved

Approved

Intermediate Coronary SyndromeApproved

Active, not recruiting

Acute Coronary SyndromeApproved

Completed

Acute Myocardial InfarctionApproved

Approved

NecrosisApproved

Terminated

Myocardial InfarctionApproved

Active, not recruiting

Recurrent ThrombophlebitisApproved

Active, not recruiting

Myocardial IschemiaApproved

Approved

Brain InfarctionApproved

Approved

Septic ShockApproved

Approved

Competition

Competitive Landscape

147 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Integrilin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Amaryl

Micardis

Boehringer Ingelheim

Advil

Cleviprex

CChiesi USA, Inc.

Imdur

Colcrys

Jazz Pharmaceuticals

Pelacarsen

Cagrilintide

Obicetrapib

NNewAmsterdam Pharma

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Not yet recruiting

Ischemic Stroke

NCT07347626

Clinical

Trials by Indication[1]

Ischemic stroke5 trials

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

Completed·UUniversity of Cincinnati·Phase 2·NCT00894803·126 enrolled

Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis

Not yet recruiting·XXinqiao Hospital of Chongqing·Phase 3·NCT07347626·786 enrolled

Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH)

Unknown status·MMinistry of Science and Technology of the People´s Republic of China·Phase 3·NCT03844594·220 enrolled

Show 2 more trials

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)

Completed·AArthur Pancioli·Phase 2·NCT01977456·27 enrolled

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00061373·18 enrolled

Acute Coronary Syndrome3 trials

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

Completed· Sanofi logo

Sanofi·Phase 2·NCT00317395·3,241 enrolled

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

Completed·MMedical University of Silesia·Phase 4·NCT01863134·140 enrolled

EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00089895·9,406 enrolled

Percutaneous Coronary Intervention2 trials

BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

Completed·CCardiology Research UBC·Phase 4·NCT00111566·624 enrolled

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

Completed·MMedicure·Phase 2·NCT01522417·535 enrolled

Necrosis2 trials

The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)

Terminated·UUniversity of Turin, Italy·Phase 4·NCT01454440·91 enrolled

INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial

Completed·FFondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS·Phase 3·NCT00638976·91 enrolled

ST Elevation Myocardial Infarction2 trials

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

Completed· Sanofi logo

Sanofi·Phase 3·NCT01076764·13,220 enrolled

Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)

Completed· GSK logo

GSK·Phase 3·NCT00426751·429 enrolled

7 more indications

Infusion1 trial

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT01919723·70 enrolled

Sickle Cell Disease1 trial

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 1/2·NCT00834899·13 enrolled

Heart Attack1 trial

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

Terminated·—·Phase 2·NCT00719914·31 enrolled

Clopidogrel1 trial

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02925923·100 enrolled

Randomized1 trial

Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty

Terminated·—·Phase 4·NCT00289601·1,200 enrolled

Effectiveness1 trial

Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients

Unknown status·—·Phase 2·NCT00945308·50 enrolled

Stroke1 trial

Multi-arm Optimization of Stroke Thrombolysis

Completed·WWashington University School of Medicine·Phase 3·NCT03735979·514 enrolled

Regulatory

FDA Approval Timeline[5]

May 18, 1998

INTEGRILIN

NDA NDA020718

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for eptifibatide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Integrilin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — eptifibatide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for eptifibatide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020718). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Integrin Alpha-Iib/beta-3 Inhibitor[3]
Modality: Peptide[3]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Related News